Neuroeconomics is the multidisciplinary study of value-based decision-making. One of the core topics is how emotions affect decision-making. Developments in economic models of decision-making have been influenced by technological innovations and empirical findings in cognitive neuroscience. Now, a recent approach in cognitive neuroscience, often referred to as “imaging genetics”, promises to make significant contributions to our understanding of both behavioral and neural aspects of value-based decision-making. Recent work has demonstrated the role of neurotransmitter alterations in clinical states such as Parkinson’s disease, depression and anxiety, and how this may affect decision behavior. However, these insights are limited through their focus on extreme neuropathology, which sheds little light on similar functions in healthy individuals. Here, we present and discuss studies of the role of drug-induced and genetically driven changes in neurotransmitter levels, and their effects on value-based decision-making. Following this, we argue that in healthy subjects, individual variance in decision behavior can be explained by such genetic factors, and gene–environment interactions. We suggest that this development should be used in neuroeconomic research in order to both improve behavioral models, by stressing the biological nature of individual variance, and through the improvement of our general understanding of the brain basis of value-based decision-making.